| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
12.40(B) |
| Last
Volume: |
779,523 |
Avg
Vol: |
420,575 |
| 52
Week Range: |
$205.19 - $258.13 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
466,605 |
506,610 |
569,867 |
1,758,988 |
| Total Sell Value |
$110,691,046 |
$119,828,977 |
$133,965,406 |
$428,642,279 |
| Total People Sold |
5 |
6 |
6 |
10 |
| Total Sell Transactions |
49 |
58 |
71 |
248 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-03-05 |
4 |
OE |
$129.49 |
$815,787 |
D/D |
6,300 |
6,430 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-03-04 |
4 |
AS |
$230.58 |
$212,071 |
D/D |
(915) |
130 |
|
15% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-03-04 |
4 |
OE |
$129.49 |
$118,483 |
D/D |
915 |
1,045 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-03-01 |
4 |
AS |
$231.11 |
$3,493,352 |
D/D |
(15,000) |
130 |
|
13% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-03-01 |
4 |
OE |
$129.49 |
$1,942,350 |
D/D |
15,000 |
15,130 |
|
- |
|
| Thompson Tommy G |
|
– • – |
2024-03-01 |
4 |
D |
$231.92 |
$463,840 |
D/D |
(2,000) |
8,480 |
|
- |
|
| Thompson Tommy G |
|
– • – |
2024-03-01 |
4 |
OE |
$88.03 |
$176,060 |
D/D |
2,000 |
10,480 |
|
- |
|
| Kurzweil Ray |
|
– • – |
2024-02-23 |
4 |
D |
$227.03 |
$3,405,450 |
D/D |
(15,000) |
11,180 |
|
- |
|
| Kurzweil Ray |
|
– • – |
2024-02-23 |
4 |
OE |
$88.03 |
$1,320,450 |
D/D |
15,000 |
26,180 |
|
- |
|
| Thompson Tommy G |
|
– • – |
2024-02-23 |
4 |
D |
$227.03 |
$454,060 |
D/D |
(2,000) |
8,480 |
|
- |
|
| Thompson Tommy G |
|
– • – |
2024-02-23 |
4 |
OE |
$88.03 |
$176,060 |
D/D |
2,000 |
10,480 |
|
- |
|
| Patusky Christopher |
|
– • – |
2024-02-23 |
4 |
S |
$224.00 |
$376,320 |
D/D |
(1,680) |
4 |
|
-14% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2024-02-15 |
4 |
AS |
$214.54 |
$1,291,885 |
D/D |
(6,000) |
36,599 |
|
22% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2024-02-15 |
4 |
OE |
$117.76 |
$706,560 |
D/D |
6,000 |
42,599 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2024-02-01 |
4 |
AS |
$213.58 |
$1,290,083 |
D/D |
(6,000) |
36,599 |
|
22% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2024-02-01 |
4 |
OE |
$117.76 |
$706,560 |
D/D |
6,000 |
42,599 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2024-01-18 |
4 |
AS |
$217.55 |
$1,312,322 |
D/D |
(6,000) |
36,599 |
|
20% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2024-01-18 |
4 |
OE |
$117.76 |
$706,560 |
D/D |
6,000 |
42,599 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2024-01-04 |
4 |
AS |
$227.34 |
$1,367,798 |
D/D |
(6,000) |
36,599 |
|
14% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2024-01-04 |
4 |
OE |
$117.76 |
$706,560 |
D/D |
6,000 |
42,599 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2023-12-21 |
4 |
AS |
$223.94 |
$1,375,605 |
D/D |
(6,000) |
36,599 |
|
20% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2023-12-21 |
4 |
OE |
$117.76 |
$706,560 |
D/D |
6,000 |
42,599 |
|
- |
|
| Mesa Nilda |
|
– • – |
2023-12-19 |
4 |
S |
$244.90 |
$148,165 |
D/D |
(605) |
5,698 |
|
-6% |
|
| Causey Christopher |
|
– • – |
2023-12-15 |
4 |
S |
$255.00 |
$102,000 |
D/D |
(400) |
4,185 |
|
3% |
|
| Causey Christopher |
|
– • – |
2023-12-12 |
4 |
S |
$249.68 |
$749,034 |
D/D |
(3,000) |
4,585 |
|
6% |
|
2674 Records found
|
|
Page 5 of 107 |
|
|
4.27 (1.65%) 
